

# HER2 Activating Mutations Are Targets for Colorectal C

Cancer Discovery

5, 832-841

DOI: [10.1158/2159-8290.cd-14-1211](https://doi.org/10.1158/2159-8290.cd-14-1211)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 75.	1.0	5
2	ERBB2 Emerges as a New Target for Colorectal Cancer. <i>Cancer Discovery</i> , 2015, 5, 799-801.	7.7	21
3	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015, 526, 263-267.	13.7	398
4	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016, 7, 69060-69074.	0.8	29
5	Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. , 2016, 166, 71-83.		14
6	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
7	Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. <i>Journal of Clinical Pathology</i> , 2016, 69, 767-771.	1.0	75
8	Spectrum of Gene Mutations in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 149-155.	1.0	22
9	Mechanisms of tumor cell resistance to the current targeted-therapy agents. <i>Tumor Biology</i> , 2016, 37, 10021-10039.	0.8	60
10	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36
11	Testing <i>ERBB2</i> p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001016.	0.5	5
12	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 267-282.	1.0	7
13	Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. <i>Tumor Biology</i> , 2016, 37, 11645-11655.	0.8	21
14	How Can Gastric Cancer Molecular Profiling Guide Future Therapies?. <i>Trends in Molecular Medicine</i> , 2016, 22, 534-544.	3.5	50
15	<i>HER2</i> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <i>QUASAR</i> , <i>FOCUS</i> and <i>PICCOLO</i> colorectal cancer trials. <i>Journal of Pathology</i> , 2016, 238, 562-570.	2.1	185
17	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	1.5	46
18	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	12.8	527
19	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22

#	ARTICLE	IF	CITATIONS
20	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	7.7	85
21	<i>HER2</i> as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, 247-251.	1.0	32
22	Genetically engineered mouse models in oncology research and cancer medicine. <i>EMBO Molecular Medicine</i> , 2017, 9, 137-153.	3.3	356
23	Prolonged Response to <i>HER2</i> -Directed Therapy in a Patient With <i>HER2</i> -Amplified, Rapidly Progressive Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 3-8.	2.3	25
24	Rationally co-targeting divergent pathways in <i>KRAS</i> wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and <i>ErbB2</i> . <i>Scientific Reports</i> , 2017, 7, 1502.	1.6	20
25	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 145-159.	0.9	1
26	Utility of comprehensive genomic sequencing for detecting <i>HER2</i> -positive colorectal cancer. <i>Human Pathology</i> , 2017, 66, 1-9.	1.1	31
27	Intrinsic <i>HER2</i> V777L mutation mediates resistance to trastuzumab in a breast cancer patient. <i>Medical Oncology</i> , 2017, 34, 3.	1.2	31
28	High early growth response 1 ( <i>EGR1</i> ) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. <i>Clinical and Translational Oncology</i> , 2017, 19, 718-726.	1.2	13
29	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 79-92.	12.8	686
30	Prognostic Value of <i>BRAF</i> and <i>KRAS</i> Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	3.0	201
31	Preclinical mouse solid tumour models: status quo, challenges and perspectives. <i>Nature Reviews Cancer</i> , 2017, 17, 751-765.	12.8	222
32	Molecular Testing of Colorectal Cancer in the Modern Era. <i>Surgical Pathology Clinics</i> , 2017, 10, 1009-1020.	0.7	4
33	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017, 28, 3009-3014.	0.6	72
34	<i>RUBCN</i> /rubicon and <i>EGFR</i> regulate lysosomal degradative processes in the retinal pigment epithelium (RPE) of the eye. <i>Autophagy</i> , 2017, 13, 2072-2085.	4.3	57
35	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. <i>Future Oncology</i> , 2017, 13, 1999-2006.	1.1	2
36	Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types. <i>Scientific Reports</i> , 2017, 7, 6418.	1.6	10
37	Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. <i>Scientific Reports</i> , 2017, 7, 6689.	1.6	35

#	ARTICLE	IF	CITATIONS
38	Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 107-115.	2.3	71
39	Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy. <i>Colorectal Cancer</i> , 2017, 6, 57-61.	0.8	2
40	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	5
42	Genetic Variations of Selected Genes Using Target Deep Sequencing in Colorectal Cancer Patients. <i>Journal of Cancer Science &amp; Therapy</i> , 2017, 9, .	1.7	1
43	PDX Models of Colorectal Tumors. , 2017, , 291-304.		0
44	Genomics of peritoneal surface malignancies. <i>Journal of Peritoneum (and Other Serosal Surfaces)</i> , 2017, , .	0.1	1
45	Genomic alterations of ERBB receptors in cancer: clinical implications. <i>Oncotarget</i> , 2017, 8, 114371-114392.	0.8	96
46	Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 387-404.	0.6	21
47	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 1-27.	0.1	1
48	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 1108-1119.	0.6	177
49	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	2.0	29
50	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
51	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774604.	1.4	11
52	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . <i>Cancer</i> , 2018, 124, 1358-1373.	2.0	151
53	ERBB2 mutation: A promising target in non-squamous cervical cancer. <i>Gynecologic Oncology</i> , 2018, 148, 311-316.	0.6	27
54	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. <i>Tumori</i> , 2018, 104, NP38-NP41.	0.6	1
55	The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 755-766.	2.5	39
56	Molecular Landscape of <i>ERBB2/ERBB3</i> -Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1409-1417.	3.0	53

#	ARTICLE	IF	CITATIONS
57	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 807-820.	3.2	23
58	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
60	Outcomes of Chemotherapy for Microsatellite Instable-High Metastatic Colorectal Cancers. <i>JCO Precision Oncology</i> , 2018, 2, 1-10.	1.5	15
61	The Role of HER2 Testing in Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 184-191.	1.0	2
62	Targeted Therapy of Colorectal Cancer Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
63	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 75-100.	0.8	7
64	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. <i>Cancer Cell</i> , 2018, 34, 792-806.e5.	7.7	102
65	High-Throughput Functional Evaluation of Variants of Unknown Significance in <i>ERBB2</i> . <i>Clinical Cancer Research</i> , 2018, 24, 5112-5122.	3.2	60
66	Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1559-1569.	2.0	9
67	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 31.	1.3	167
68	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-21.	0.7	60
69	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. <i>Future Oncology</i> , 2018, 14, 2437-2459.	1.1	7
70	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018, 8, .	1.5	7
71	HER2: An emerging target in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 560-571.	1.0	67
72	Association of <i>ERBB2</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	3.4	53
73	Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. <i>PLoS ONE</i> , 2018, 13, e0198141.	1.1	17
74	Genomic <i>ERBB2</i> / <i>ERBB3</i> mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. <i>Gut</i> , 2019, 68, 1024-1033.	6.1	120
75	Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. <i>Journal of Nanobiotechnology</i> , 2019, 17, 89.	4.2	40

#	ARTICLE	IF	CITATIONS
76	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6243-6259.	3.2	42
77	Emergence of <i>ERBB2</i> Mutation as a Biomarker and an Actionable Target in Solid Cancers. <i>Oncologist</i> , 2019, 24, e1303-e1314.	1.9	64
78	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	2.3	25
79	Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. <i>Theranostics</i> , 2019, 9, 3485-3500.	4.6	9
80	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48
81	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 6899-6908.	3.2	76
82	Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. <i>Cancers</i> , 2019, 11, 1581.	1.7	26
83	Human Colorectal Cancer from the Perspective of Mouse Models. <i>Genes</i> , 2019, 10, 788.	1.0	26
84	Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 16894.	1.6	8
85	The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab. <i>Biomolecules</i> , 2019, 9, 629.	1.8	10
86	Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 880.	1.1	13
87	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. <i>Cancers</i> , 2019, 11, 1321.	1.7	34
88	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
89	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 236.	3.5	17
90	HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment. <i>Cell Cycle</i> , 2019, 18, 1513-1522.	1.3	15
91	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	2.3	76
92	Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. <i>Carcinogenesis</i> , 2020, 41, 44-55.	1.3	13
93	A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2931-2936.	1.0	3

#	ARTICLE	IF	CITATIONS
94	<p>Selecting treatment options in refractory metastatic colorectal cancer</p><p>OncoTargets and Therapy, 2019, Volume 12, 2271-2278.</p>	1.0	20
95	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	5.1	362
96	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	2.0	14
97	Computational algorithms for in silico profiling of activating mutations in cancer. Cellular and Molecular Life Sciences, 2019, 76, 2663-2679.	2.4	11
98	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
99	Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 1137-1148.	1.9	0
100	Network-guided prediction of aromatase inhibitor response in breast cancer. PLoS Computational Biology, 2019, 15, e1006730.	1.5	5
101	Firstâ€line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-14.	0.7	4
102	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	1.9	16
103	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Antiâ€Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	1.5	46
104	Human epidermal growth factor receptor 2-positive digestive tumors. Current Opinion in Oncology, 2019, 31, 354-361.	1.1	4
105	<p>Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab</p><p>OncoTargets and Therapy, 2019, Volume 12, 11597-11608.</p>	1.0	12
106	HER2 + mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy. Journal of Cellular Physiology, 2019, 234, 13137-13144.	2.0	7
107	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opinion on Investigational Drugs, 2019, 28, 29-38.	1.9	32
108	Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biology and Therapy, 2019, 20, 391-396.	1.5	9
109	Human gastric cancer modelling using organoids. Gut, 2019, 68, 207-217.	6.1	204
110	HER2-targeted therapies â€ a role beyond breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 33-48.	12.5	569
111	Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clinical and Translational Oncology, 2020, 22, 813-822.	1.2	24

#	ARTICLE	IF	CITATIONS
112	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
113	Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 661-668.	0.6	7
114	lluminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
115	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1830.	1.7	2
116	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. <i>Gastroenterology Report</i> , 2020, 8, 179-191.	0.6	60
117	Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies. <i>Oncogene</i> , 2020, 39, 5867-5875.	2.6	17
118	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	40
119	Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics. <i>Frontiers in Genetics</i> , 2020, 11, 865.	1.1	10
120	Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. <i>Nature Communications</i> , 2020, 11, 4225.	5.8	47
121	Molecular Pathogenesis and Classification of Colorectal Carcinoma. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 97-106.	1.0	12
122	MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. , 2020, 213, 107577.		43
123	ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain. <i>Neurobiology of Disease</i> , 2020, 142, 104961.	2.1	13
124	&lt;p&gt;Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring &lt;em&gt;HER2&lt;/em&gt; Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4249-4255.	1.0	6
125	Somatic Mutations in <i>HER2</i> and Implications for Current Treatment Paradigms in <i>HER2</i>-Positive Breast Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	35
126	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	1.1	4
127	Establishing metastatic patient-derived xenograft model for colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1108-1116.	0.6	11
128	HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 65-72.	1.0	35
129	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. <i>Cancer Cell</i> , 2020, 37, 183-199.e5.	7.7	33



#	ARTICLE	IF	CITATIONS
130	Zebrafish Avatars towards Personalized Medicineâ€”A Comparative Review between Avatar Models. <i>Cells</i> , 2020, 9, 293.	1.8	47
131	Application of trastuzumab emtansine in HER2â€”positive and KRAS/BRAFâ€”mutated colon cancer cells. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13255.	1.7	5
133	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	1.4	2
134	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ””positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
135	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. <i>Gut</i> , 2022, 71, 119-128.	6.1	46
136	The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 126.	2.7	7
137	HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1105-1120.	2.3	4
138	Advances in Modeling the Immune Microenvironment of Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 614300.	2.2	16
139	Clinical benefit for clinical sequencing using cancer panel testing. <i>PLoS ONE</i> , 2021, 16, e0247090.	1.1	3
140	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	2.7	6
141	Application of Animal Models in Cancer Research: Recent Progress and Future Prospects. <i>Cancer Management and Research</i> , 2021, Volume 13, 2455-2475.	0.9	61
142	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. <i>Cancer Discovery</i> , 2021, 11, 1644-1660.	7.7	11
143	Precision oncology in metastatic colorectal cancer â€” from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 506-525.	12.5	113
144	Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1161-e1170.	1.9	8
145	Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 178.	3.5	27
147	Genetic and biological hallmarks of colorectal cancer. <i>Genes and Development</i> , 2021, 35, 787-820.	2.7	159
148	Preclinical models as patientsâ€™ avatars for precision medicine in colorectal cancer: past and future challenges. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 185.	3.5	20
149	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6813.	1.8	20

#	ARTICLE	IF	CITATIONS
150	Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer. Expert Review of Anticancer Therapy, 2021, 21, 1097-1104.	1.1	2
151	HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer. Endocrinology, 2021, 162, .	1.4	11
152	Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 233-246.	1.4	67
153	Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell, 2021, 39, 1099-1114.e8.	7.7	45
154	Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 9369.	1.8	15
155	The best strategy for metastatic colorectal cancer(mCRC) patients in second-line treatment: A network meta-analysis. Cancer Treatment and Research Communications, 2021, 29, 100455.	0.7	6
156	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a037820.	2.9	9
157	Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188605.	3.3	11
158	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical Cancer Research, 2021, 27, 1681-1694.	3.2	33
159	Biomarkers in the Management of Peritoneal Metastases. , 2020, , 251-279.		2
160	Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World Journal of Clinical Cases, 2018, 6, 418-425.	0.3	7
161	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
162	Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. Oncotarget, 2018, 9, 15968-15983.	0.8	15
163	Colorectal cancer genomics and designing rational trials. Annals of Translational Medicine, 2018, 6, 159-159.	0.7	19
164	&lt;p&gt;Current Molecular Targeted Agents for Advanced Gastric Cancer&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 4075-4088.	1.0	17
165	¿Existen ventajas clÃnicas al evaluar el estado de los genes KRAS, NRAS, BRAF, PIK3CA, PTEN y HER2 en pacientes con cÃncer colorrectal?. Revista Colombiana De Cirugia, 2017, 32, 45-55.	0.2	2
166	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
167	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World Journal of Gastroenterology, 2016, 22, 5668.	1.4	14

#	ARTICLE	IF	CITATIONS
168	Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World Journal of Gastroenterology, 2016, 22, 6944.	1.4	56
169	Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Journal of Experimental and Clinical Cancer Research, 2021, 40, 328.	3.5	62
170	A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI – Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. Oncology, 2021, , 1-11.	0.9	1
171	Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ, 2021, 9, e12338.	0.9	7
172	Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers. SSRN Electronic Journal, 0, , .	0.4	0
173	GI Including GIST. , 2020, , 103-122.		0
174	Development ofHER2-targeted Therapies for Gastrointestinal Cancer. European Oncology and Haematology, 2020, 16, 29.	0.0	0
175	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1
176	Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. International Biological and Biomedical Journal, 2017, 3, 105-111.	7.0	54
178	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 670-674.	2.3	4
179	Identification of an ACK1/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes. BMC Cancer, 2022, 22, 84.	1.1	3
180	Emerging actionable targets to treat therapy-resistant colorectal cancers. Cancer Drug Resistance (Alhambra, Calif ), 2022, 5, 36-63.	0.9	6
181	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	3.4	21
182	A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer. Cancer Research, 2022, 82, 1633-1645.	0.4	18
183	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	3.4	35
184	The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy. Frontiers in Molecular Biosciences, 2022, 9, 870395.	1.6	6
185	HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews, 2022, 105, 102363.	3.4	12
186	Targeted Therapy for Colorectal Cancer. Surgical Oncology Clinics of North America, 2022, 31, 255-264.	0.6	19

#	ARTICLE	IF	CITATIONS
187	Development and Validation of a Targeted “Liquid”™ NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. <i>Diagnostics</i> , 2021, 11, 2375.	1.3	3
192	Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 116-119.	2.3	4
193	A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2-advanced breast cancer patients with HER2 mutations. <i>Translational Oncology</i> , 2022, 21, 101444.	1.7	1
194	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 219-232.	1.8	21
195	HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
196	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. <i>Cancers</i> , 2022, 14, 2928.	1.7	34
197	Mind the target: human epidermal growth factor receptor 2 in colorectal cancer. <i>Current Opinion in Oncology</i> , 0, Publish Ahead of Print, .	1.1	2
198	Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, 347-353.	1.0	10
199	Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis. <i>Pharmacological Research</i> , 2022, 182, 106330.	3.1	3
200	Pozotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. <i>Cancer Research</i> , 2022, 82, 2928-2939.	0.4	7
201	HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses. <i>Cancers</i> , 2022, 14, 3519.	1.7	1
202	Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. <i>Cancers</i> , 2022, 14, 3718.	1.7	6
203	Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 873-881.	0.9	3
204	Animal Model of Inflammatory Bowel Disease Leading to Cancer and Role of Genetic Variation in Colitis-Associated Cancer. , 2022, , 1-18.		0
205	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211117.	1.4	8
206	Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy-dependent ferroptosis. <i>Drug Development Research</i> , 2022, 83, 1641-1653.	1.4	12
207	HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes. <i>Life</i> , 2022, 12, 1403.	1.1	8
208	Towards precision oncology with patient-derived xenografts. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 719-732.	12.5	33

#	ARTICLE	IF	CITATIONS
210	Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report. <i>Cancer Management and Research</i> , 0, Volume 14, 2927-2932.	0.9	1
211	Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5160.	1.7	7
212	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. <i>Cancers</i> , 2022, 14, 4834.	1.7	0
213	The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2023, 112, 102488.	3.4	6
214	Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102078.	0.7	1
215	Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2351-2361.	3.2	2
216	Driver and targetable alterations in Chinese patients with small bowel carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6139-6150.	1.2	0
217	Animal Model of Inflammatory Bowel Disease Leading to Cancer and Role of Genetic Variation in Colitis-Associated Cancer. , 2023, , 697-714.		0
218	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. <i>World Journal of Gastroenterology</i> , 0, 29, 926-948.	1.4	4
220	HER2 ~neu~™ promise for mCRC. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 8, 3-8.	0.0	0
221	Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. <i>World Journal of Gastroenterology</i> , 0, 29, 1395-1426.	1.4	8
222	Patient-derived xenograft models in cancer therapy: technologies and applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	35
236	Molecular testing in colorectal cancer. , 2024, , 339-358.		0
244	Biomarkers and theranostics in colorectal cancer. , 2024, , 329-385.		0